A study from Yale University today in JAMA Network Open reveals substantial protection by the preventive drug nirsevimab ...

AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. Read why ...

Estimated effectiveness was 65% against hospitalization, 74% against pediatric intensive care unit admission, and 64% against ...

Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.

Hamilton families have one last chance to get their babies immunized against a common virus that can cause serious lung infections before a clinic at McMaster Children’s Hospital closes. The ...

Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about ...

vaccine for pregnant individuals and the monoclonal antibody nirsevimab (Beyfortus) for newborns—has shown high uptake in a recent cohort study. 1 Conducted at a single academic center ...

Dupixent generated over €13 billion and Beyfortus reached blockbuster status with €1.7 billion in its first full year. SNY’s EPS came in at €7.12, growing 4.1% at CER, outperforming ...

The main reason appears to be the new preventative medication Beyfortus, according to reports from Het Nieuwsblad, De Standaard, Gazet van Antwerpen, and Het Belang van Limburg on Monday. The drug has ...

Usually, MMWR includes three full studies. New data from Spain show Beyfortus, the antibody injection that protects babies from RSV, was highly protective there during the first year of its rollout.

AstraZeneca’s AZN fourth-quarter 2024 core earnings of $1.05 per American depositary share (“ADS”) missed the Zacks Consensus Estimate of $1.07. Core earnings of $2.09 per share rose 44% ...

Revenue is anticipated to grow by a high single-digit percentage at CER The adjusted EBITA margin is anticipated to be in the mid-30s percentage of revenue 1. Alternative Performance Measures ...